1357171-62-0
中文名稱
KC7F2
英文名稱
ML-228
CAS
1357171-62-0
分子式
C27H21N5
分子量
415.49
MOL 文件
1357171-62-0.mol
更新日期
2024/12/03 15:40:31
1357171-62-0 結(jié)構(gòu)式
基本信息
中文別名
化合物ML228 英文別名
L-228ML-228
CID-46742353
ML228
ML 228
ML-228
CID-46742353
N-([1,1'Biphenyl]-4-ylmethyl)-6-phenyl-3-(2-pyridinyl)-1,2,4-triazin-5-amine
N-([1,1-Biphenyl]-4-ylmethyl)-6-phenyl-3-(pyridin-2-yl)-1,2,4-triazin-5-amine
1,2,4-Triazin-5-amine, N-([1,1'-biphenyl]-4-ylmethyl)-6-phenyl-3-(2-pyridinyl)-
所屬類別
生物化工：激動劑抑制劑物理化學(xué)性質(zhì)
沸點686.0±65.0 °C(Predicted)
密度1.228±0.06 g/cm3(Predicted)
儲存條件-20°C, Inert atmosphere
溶解度可溶于DMSO（少許）、甲醇（少許）
酸度系數(shù)(pKa)2.03±0.63(Predicted)
形態(tài)固體
顏色淡黃色至淡黃色
常見問題列表
生物活性
ML228 (CID-46742353) 是一種有效的 HIF 信號通路激活劑，EC50 為 1 μM。ML228 可激活 HIF 以及下游 EGFR。靶點
EC50: 1 μM (HIF)
體外研究
ML228 (CID-46742353) represents a novel chemotype available to the research community for the study of HIF activation and its therapeutic potential. Not only is the compound substantially different in structure from known HIF activators, ML228 lacks the acidic functional group almost universally present in PHD inhibitors, which may be important for certain disease applications.
體內(nèi)研究
ML228 (injection; 1 μg/kg; 7 days) treatments following spinal cord injury (SCI) improves the local hypoxic ischemia environment, reduce SCI secondary injury and promote the recovery of neurological function.
| Animal Model: | SD rat |
| Dosage: | 1 μg/kg |
| Administration: | injection; 7 days |
| Result: | Alleviated SCI of the central nervous system and relieve associated symptoms. |